Ulobetasol Propionate
Ulobetasol Propionate - General Information
Halobetasol propionate is thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. It is used for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Pharmacology of Ulobetasol Propionate
Not Available
Ulobetasol Propionate for patients
Patients using topical corticosteroids should receive the following information and instructions:
1. The medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
2. The medication should not be used for any disorder other than that for which it was prescribed.
3. The treated skin area should not be bandaged, otherwise covered or wrapped, so as to be occlusive unless directed by the physician.
4. Patients should report to their physician any signs of local adverse reactions.
5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressing.
Ulobetasol Propionate Interactions
No information provided.
Ulobetasol Propionate Contraindications
ULTRAVATE (halobetasol propionate cream) Cream is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Additional information about Ulobetasol Propionate
Ulobetasol Propionate Indication: For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Mechanism Of Action: Halobetasol propionate is thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Halobetasol Propionate
Synonyms: Not Available
Drug Category: Anti-inflammatory Agents; Vasoconstrictor Agents
Drug Type: Small Molecule; Approved
Other Brand Names containing Halobetasol Propionate: Halobetasol; Ulobetasol Propionate; Ultravate;
Absorption: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity of the epidermal barrier. Inflammation and/or other disease processes in the skin may increase percutaneous absorption.
Toxicity (Overdose): Not Available
Protein Binding: Not Available
Biotransformation: Not Available
Half Life: Not Available
Dosage Forms of Ulobetasol Propionate: Ointment Topical
Cream Topical
Chemical IUPAC Name: [(6S,9R,16S,17R)-17-(2-chloroacetyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate
Chemical Formula: C25H31ClF2O5
Halobetasol Propionate on Wikipedia: Not Available
Organisms Affected: Humans and other mammals
